HRP20130969T1 - Spojevi spiropiperidona kao antagonisti receptora orl-1 - Google Patents

Spojevi spiropiperidona kao antagonisti receptora orl-1 Download PDF

Info

Publication number
HRP20130969T1
HRP20130969T1 HRP20130969AT HRP20130969T HRP20130969T1 HR P20130969 T1 HRP20130969 T1 HR P20130969T1 HR P20130969A T HRP20130969A T HR P20130969AT HR P20130969 T HRP20130969 T HR P20130969T HR P20130969 T1 HRP20130969 T1 HR P20130969T1
Authority
HR
Croatia
Prior art keywords
pharmaceutically acceptable
acceptable salt
methyl
fluorine
compound according
Prior art date
Application number
HRP20130969AT
Other languages
English (en)
Croatian (hr)
Inventor
Ana Belen Benito Collado
Nuria Diaz Buezo
Alma Maria Jimenez-Aguado
Celia Lafuente Blanco
Maria Angeles Martinez-Grau
Concepcion Pedregal-Tercero
Miguel Angel Toledo Escribano
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20130969T1 publication Critical patent/HRP20130969T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HRP20130969AT 2009-11-16 2010-11-12 Spojevi spiropiperidona kao antagonisti receptora orl-1 HRP20130969T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09382245 2009-11-16
US29862810P 2010-01-27 2010-01-27
PCT/US2010/056449 WO2011060217A1 (en) 2009-11-16 2010-11-12 Spiropiperidine compounds as orl-1 receptor antagonists

Publications (1)

Publication Number Publication Date
HRP20130969T1 true HRP20130969T1 (hr) 2013-11-22

Family

ID=41800752

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20130969AT HRP20130969T1 (hr) 2009-11-16 2010-11-12 Spojevi spiropiperidona kao antagonisti receptora orl-1

Country Status (18)

Country Link
US (1) US20120214784A1 (enExample)
EP (1) EP2501704B1 (enExample)
JP (1) JP5723381B2 (enExample)
KR (1) KR101368130B1 (enExample)
CN (1) CN102666550B (enExample)
AU (1) AU2010319400B2 (enExample)
BR (1) BR112012011710A2 (enExample)
CA (1) CA2781041C (enExample)
DK (1) DK2501704T3 (enExample)
EA (1) EA020391B1 (enExample)
ES (1) ES2436241T3 (enExample)
HR (1) HRP20130969T1 (enExample)
MX (1) MX2012005690A (enExample)
PL (1) PL2501704T3 (enExample)
PT (1) PT2501704E (enExample)
RS (1) RS53017B (enExample)
SI (1) SI2501704T1 (enExample)
WO (1) WO2011060217A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011069063A2 (en) * 2009-12-04 2011-06-09 Sunovion Pharmaceuticals, Inc. Multicyclic compounds and methods of use thereof
TWI582096B (zh) * 2011-12-06 2017-05-11 美國禮來大藥廠 用於酒精依賴及濫用處理之4',5'-二氫螺[哌啶-4,7'-噻吩并[2,3-c]哌喃]化合物
TW201416370A (zh) 2012-07-31 2014-05-01 Lilly Co Eli 用於治療焦慮之orl-1受體拮抗劑
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
JO3638B1 (ar) * 2015-09-09 2020-08-27 Lilly Co Eli مركبات مفيدة في تثبيط ror - جاما- t
AU2017301767A1 (en) 2016-07-29 2019-02-14 Pgi Drug Discovery Llc Compounds and compositions and uses thereof
HUE070203T2 (hu) 2016-07-29 2025-05-28 Sumitomo Pharma America Inc Vegyületek és készítmények és alkalmazásaik
KR20190037305A (ko) 2016-08-10 2019-04-05 바이엘 크롭사이언스 악티엔게젤샤프트 해충 방제제로서의 치환된 2-헤테로시클릴 이미다졸릴-카르복스아미드
WO2018151861A1 (en) 2017-02-16 2018-08-23 Sunovion Pharamaceuticials Inc. Methods of treating schizophrenia
SI3589638T1 (sl) 2017-03-02 2021-08-31 Eli Lilly And Company Spojine uporabne pri inhibiciji ROR-GAMMA-T
RS61935B1 (sr) * 2017-03-02 2021-07-30 Lilly Co Eli Jedinjenja korisna za inhibiciju ror-gama-t
AU2018312559B2 (en) 2017-08-02 2022-06-02 Pgi Drug Discovery Llc Isochroman compounds and uses thereof
CA3091292A1 (en) 2018-02-16 2019-08-22 Sunovion Pharmaceuticals Inc. Salts, crystal forms, and production methods thereof
IL283592B2 (en) 2018-12-17 2025-08-01 Vertex Pharma Inhibitors of apol1 and methods of using same
KR20210139376A (ko) 2019-03-14 2021-11-22 선오비온 파마슈티컬스 인코포레이티드 이소크로마닐 화합물의 염, 및 이의 결정성 형태, 제조방법, 치료 용도 및 약제학적 조성물
EP3766879A1 (en) 2019-07-19 2021-01-20 Basf Se Pesticidal pyrazole derivatives
EP4135690A1 (en) 2020-04-14 2023-02-22 Sunovion Pharmaceuticals Inc. (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders
MX2023002269A (es) 2020-08-26 2023-05-16 Vertex Pharma Inhibidores de apol1 y metodos para usar los mismos.
AU2023218994A1 (en) * 2022-02-08 2024-08-22 Vertex Pharmaceuticals Incorporated 2-methyl-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2003095427A1 (ja) 2002-05-10 2005-09-15 大正製薬株式会社 スピロ環化合物
WO2005016913A1 (en) * 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
DE10360792A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
US7354925B2 (en) * 2004-03-29 2008-04-08 Pfizer Inc. Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as ORL1-receptor antagonists
DE102004039382A1 (de) * 2004-08-13 2006-02-23 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
JP2008542375A (ja) * 2005-06-02 2008-11-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Orl−1受容体モジュレーターとして有用な新規3−スピロ環式インドリル誘導体

Also Published As

Publication number Publication date
KR101368130B1 (ko) 2014-02-27
JP2013510870A (ja) 2013-03-28
MX2012005690A (es) 2012-06-13
KR20120082927A (ko) 2012-07-24
ES2436241T3 (es) 2013-12-27
SI2501704T1 (sl) 2013-11-29
EP2501704B1 (en) 2013-09-18
BR112012011710A2 (pt) 2016-03-01
JP5723381B2 (ja) 2015-05-27
EP2501704A1 (en) 2012-09-26
RS53017B (sr) 2014-04-30
EA201290355A1 (ru) 2012-10-30
CA2781041C (en) 2015-01-06
CN102666550B (zh) 2015-07-15
WO2011060217A1 (en) 2011-05-19
US20120214784A1 (en) 2012-08-23
AU2010319400B2 (en) 2013-12-19
EA020391B1 (ru) 2014-10-30
CN102666550A (zh) 2012-09-12
AU2010319400A1 (en) 2012-06-07
DK2501704T3 (da) 2013-10-14
PL2501704T3 (pl) 2014-02-28
PT2501704E (pt) 2013-12-05
CA2781041A1 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
HRP20130969T1 (hr) Spojevi spiropiperidona kao antagonisti receptora orl-1
HRP20130967T1 (hr) Spojevi spiropiperidona kao antagonisti receptora orl-1
JP2013510870A5 (enExample)
HRP20170363T1 (hr) Derivati piridina kao inhibitori kinaze pregrađene prilikom transfekcije (ret)
JP2016516026A5 (enExample)
JP2013510859A5 (enExample)
SI2978752T1 (en) 6- (5-Hydroxy-1H-pyrazol-1-yl) nicotinamide derivatives and their use as inhibitors of PHD
HRP20200781T1 (hr) DERIVATI PIRAZOLO[1,5-a]PIRAZIN-4-ILA KAO INHIBITORI JAK
RU2015143430A (ru) Новые соединения и фармацевтические композиции, их содержащие, для лечения воспалительных расстройств
PE20140570A1 (es) Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos
MX2020005874A (es) Acidos carbamoil ciclohexilicos n-enlazados a pirazol como antagonistas de receptores del acido lisofosfatidico (lpa).
HRP20180528T1 (hr) Derivati naftiridina, korisni kao antagonisti alfa-v-beta-6 integrina
RU2014105624A (ru) Соединения индазола, способ их применения и фармацевтическая композиция
EP3322711A1 (en) Hpk1 inhibitors and methods of using same
NZ601077A (en) Use of an adrenal hormone-modifying agent
CA2915536A1 (en) Indolin-2-one or pyrrolo-pyridin/pyrimidin-2-one derivatives
HRP20180382T1 (hr) Inhibitori protein kinaze
RU2011125314A (ru) Новое производное пиразол-3-карбоксамида, обладающее антагонистической активностью в отношении рецептора 5-нт2в
NZ603777A (en) Bicyclic compound derivatives and their use as acc inhibitors.
RU2017120217A (ru) 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1
CN109790158A (zh) 作为jak抑制剂杂环化合物,该化合物的盐类及其治疗用途
RU2015148766A (ru) Комбинации лигандов альфа-2 адренорецептора и сигма рецептора
EA201200903A1 (ru) Гербицидно активные заместители 2-(замещенного-фенила)циклопентан-1,3-диона
HRP20161351T1 (hr) Derivati spirotienopiranopiperidina kao antagonisti receptora orl-1, namijenjeni upotrebi u liječenju ovisnosti o i zloupotrebi alkohola
RU2016102149A (ru) Применение сигма-лигандов для предотвращения и лечения боли, связанной с интерстициальным циститом/синдромом раздраженного мочевого пузыря (иц/срмп)